MGAT2

MGAT2 is a bifunctional gene whose product carries out two mechanistically distinct enzymatic activities in different subcellular and tissue contexts. In the Golgi it functions as N-acetylglucosaminyltransferase II (GnT-II), a 447-residue type II transmembrane enzyme with a short cytoplasmic tail, a signal-anchor transmembrane domain, and a C-terminal catalytic domain that transfers GlcNAc onto the α-6-mannose arm of N-glycans, the committed step converting oligomannose to complex N-glycans (PMID:7635144). This activity is essential in vivo: Mgat2-null mice lose complex N-glycan synthesis and develop severe gastrointestinal, hematologic, and osteogenic defects with early postnatal lethality (PMID:12417412), and loss-of-function point mutations in the catalytic domain abolish GnT-II activity and cause congenital disorder of glycosylation type IIa (CDG-IIa) in humans (PMID:8808595). Complex N-glycan branching generated by MGAT2 is required for distinct cellular programs: in antigen-presenting cells it enables MHC class II-dependent glycoantigen presentation and T-cell activation (PMID:24310166), and in spermatogonia it is required for progression through spermatogenesis, with its loss derepressing AKT and ERK1/2 signaling and blocking round spermatid formation (PMID:39364139). Separately, MGAT2 acts in the intestinal ER as an acyl-CoA:monoacylglycerol acyltransferase that synthesizes diacylglycerol from monoacylglycerol and fatty acyl-CoA, with an additional intrinsic DGAT activity distinguishable by detergent sensitivity (PMID:12621063, PMID:12576479, PMID:12730219). In this role it physically associates with DGAT2 through DGAT2's transmembrane domains, co-localizing at the ER and lipid droplets to channel substrates for triglyceride synthesis (PMID:25164810), and MGAT2-dependent triglyceride re-synthesis is required for postprandial GIP secretion after dietary fat (PMID:19732742).

1. 1995 High

   Established the molecular identity, domain architecture, and chromosomal locus of the glycosyltransferase GnT-II and confirmed its catalytic product, defining the enzyme that commits N-glycans to the complex pathway.

   Evidence Genomic cloning, baculovirus/Sf9 purification, in vitro assay, NMR/MS product identification, and FISH mapping

   PMID:7635144

   Open questions at the time

   • No atomic structure of the catalytic domain
   • Mechanism of acceptor mannose-arm recognition not resolved
2. 1996 High

   Linked MGAT2 to human disease by showing catalytic-domain point mutations inactivate GnT-II, establishing it as the causal gene for CDG type IIa.

   Evidence Patient mutation identification with baculovirus expression of mutant proteins and enzyme activity assays in two unrelated families

   PMID:8808595

   Open questions at the time

   • Genotype-phenotype range across CDG-IIa patients not addressed
   • How partial loss of branching produces specific clinical features unknown
3. 1998 Medium

   Characterized the MGAT2 promoter as a TATA-less, GC-rich housekeeping-type promoter, addressing how the gene is constitutively transcribed.

   Evidence 5'/3'-RACE, RNase protection, and promoter-CAT deletion series in HeLa cells

   PMID:9579808

   Open questions at the time

   • Tissue-specific regulation not addressed
   • Identity of trans-acting factors at the core promoter not resolved here
4. 2000 Medium

   Identified Ets transcription factors as activators of MGAT2 transcription and distinguished its regulation from GnT-V, beginning to define upstream control of branching enzyme expression.

   Evidence Reporter co-transfection, EMSA, and South-Western blot with src/neu negative controls in HepG2/COS-1 cells

   PMID:10749681

   Open questions at the time

   • Physiological contexts driving Ets-dependent induction unknown
   • Only one of four candidate Ets sites mapped as functional
5. 2002 High

   Demonstrated in vivo that MGAT2 is indispensable for complex N-glycan biosynthesis and organismal viability, and revealed compensatory novel glycan structures in its absence.

   Evidence Mgat2-null mouse with tissue enzyme assays and kidney N-glycan structural analysis

   PMID:12417412

   Open questions at the time

   • Tissue-specific contributions to lethality not dissected
   • Mechanism by which bisected hybrid glycans arise not detailed
6. 2003 High

   Revealed an entirely separate lipid-metabolic activity, showing MGAT2 catalyzes diacylglycerol synthesis (MGAT activity) and harbors an additional intrinsic DGAT activity, reframing the gene as bifunctional.

   Evidence Heterologous expression in insect/mammalian cells and recombinant E. coli protein with in vitro assays, detergent discrimination, and substrate specificity/cofactor panels

   PMID:12576479 PMID:12621063 PMID:12730219

   Open questions at the time

   • How a single protein partitions between Golgi glycosyltransfer and ER acyltransferase functions is unexplained
   • Physiological relevance of the intrinsic DGAT activity in vivo not established
7. 2009 Medium

   Connected MGAT2-dependent triglyceride re-synthesis to postprandial endocrine signaling, showing it is selectively required for GIP but not GLP-1/PYY secretion after dietary fat.

   Evidence MGAT2-KO mouse oral triglyceride tolerance test with plasma gut peptide measurements

   PMID:19732742

   Open questions at the time

   • Whether the effect is due to TG re-synthesis per se or chylomicron secretion not separated
   • Cell-autonomous role in enteroendocrine cells not tested
8. 2013 Medium

   Defined a function for complex N-glycan branching in immunity, showing MGAT2-dependent branching on antigen-presenting cells is required for MHC class II-dependent glycoantigen presentation.

   Evidence Myeloid-specific (LyzM-Cre) conditional Mgat2 knockout with T-cell activation, antigen uptake, and homing assays

   PMID:24310166

   Open questions at the time

   • Which surface glycoproteins mediate the effect not identified
   • Mechanism linking branching to glycoantigen loading not resolved
9. 2014 High

   Provided a structural mechanism for efficient triglyceride synthesis by showing MGAT2 physically partners with DGAT2 via DGAT2 transmembrane domains, supporting substrate channeling at the ER/lipid droplet.

   Evidence Reciprocal Co-IP, proximity ligation, DSS cross-linking, DGAT2 deletion mutagenesis, co-localization imaging, and TG storage quantification

   PMID:25164810

   Open questions at the time

   • Direct evidence of metabolite channeling (vs. co-localization) not shown
   • Stoichiometry and architecture of the complex unknown
10. 2024 Medium

    Extended the in vivo importance of MGAT2 branching to spermatogenesis and revealed that loss alters intracellular signaling, distinguishing MGAT2 from MGAT1.

    Evidence Stra8-iCre conditional KO with lectin binding, RNA-seq, histology, and Western blot for AKT/ERK1/2

    PMID:39364139

    Open questions at the time

    • Glycoprotein substrates controlling germ cell signaling not identified
    • Causal link between altered AKT/ERK and the spermatogenic block not established
11. 2024 Medium

    Began to define the supramolecular organization of branching enzymes by detecting MGAT1-MGAT2 hetero- and homomeric complexes and their ER-to-Golgi trafficking in living cells.

    Evidence NanoBiT split-luciferase complementation with bioluminescence subcellular imaging

    PMID:39083973

    Open questions at the time

    • Single-method PPI evidence without orthogonal validation
    • Functional consequence of MGAT1-MGAT2 heteromers for glycan processing unknown

• How a single MGAT2 polypeptide is partitioned and regulated between its Golgi glycosyltransferase role and its ER lipid acyltransferase role remains unresolved.
• No mechanism reconciling dual localization and dual catalytic functions
• No structural model integrating GnT-II and MGAT/DGAT activities
• Relative physiological weighting of the two functions across tissues unquantified